Table 4.
Interferon alpha-2b pharmacokinetic parameters in the single and multiple dose phases.
| Initial single dose | Final multiple dose | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tmax (hr) | Cmax (IU mL−1) | AUC(0,24 hr) (IU.hr mL−1) | T1/2 (hr) | Tmax (hr) | Cmax (IU mL−1) | AUC(0,24 hr) (IU.hr mL−1) | T1/2 (hr) | RAUC | |
| Sustained virological responders (n = 5) | 6.0 (6.0–6.0) | 37.8 (30.1–43.7) | 480 (431–535) | 5.1 (3.0–10.6) | 6.0 (3.8–7.0) | 60.6 (32.6–109.8) | 900 (592–1346) | 6.2 (5.5–24.4) | 1.8 (1.6–2.7) |
| Virological responders (n = 16) | 6.0 (4.4–6.8) | 29.1 (25.7–42.5) | 401 (357–569) | 8.4 (7.0–9.4) | 6.0 (4.8–6.0) | 65.7 (51.7–80.7) | 896 (714–1338) | 9.3 (6.8–17.4) | 2.3 (2.0–2.6) |
| Non-responders (n = 6) | 6.0 (4.2–6.8) | 32.5 (25.8–57.0) | 482 (379–797) | 8.6 (6.5–10.5) | 6.0 (3.5–9.5) | 56.6 (36.4–101.4) | 869 (594–1694) | 12.0 (7.9–19.1) | 1.7 (1.3–4.5) |
| Total (n = 27) | 6.0 (5.0–6.4) | 32.0 (30.0–41.4) | 454 (411–559) | 8.3 (7.1–8.9) | 6.0 (5.0–6.4) | 61.2 (56.3–78.5) | 883 (794–1226) | 9.3 (8.6–15.8) | 2.0 (1.9–2.7) |
Values expressed as median. (95% confidence interval). Accumulation index (R) = AUC of week 24 / AUC of week 1.